Alumis

Alumis Liabilities

The The Liabilities of Alumis (ALMS) as of Nov 3, 2026 is 110.64 M USD. In the previous year, The Liabilities was 80.89 M USD — a change of 36.78% (higher).

Liabilities

110.64 MUSD

YoY

36.78%

Last updated:

In 2025, Alumis's total liabilities amounted to 110.64 M USD, a 36.78% difference from the 80.89 M USD total liabilities in the previous year.

The Alumis Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2022
303.41 M USD
Jan 1, 2023
428.87 M USD
Jan 1, 2024
80.89 M USD
Jan 1, 2025
110.64 M USD
The Alumis Liabilities history
YEARLiabilitiesYoY
110.64 MUSD+36.78%
80.89 MUSD-81.14%
428.87 MUSD+41.35%
303.41 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alumis Stock analysis

What does Alumis do? Alumis Inc develops TYK2 inhibitors ESK-001 and A-005 for immune-mediated and neuroinflammatory diseases. ESK-001 targets plaque psoriasis, systemic lupus erythematosus, and Uveitis as a second-generation allosteric inhibitor. A-005 is designed as a CNS-penetrant molecule for neurodegenerative conditions. The company builds a pipeline using data analytics to identify targets for immune-mediated indications. Its products are developed for clinical-stage biopharmaceutical use, targeting specific disease mechanisms with optimized tolerability. The company focuses on developing therapies as monotherapy or combination treatments for immune-mediated diseases. ESK-001 maximizes target inhibition while optimizing tolerability for psoriasis and lupus. A-005 delivers TYK2 inhibition within the central nervous system for neuroinflammatory diseases. The pipeline includes early-stage discovery assets identified through the company's data analytics platform, targeting immune-mediated conditions without specifying additional therapeutic applications. Alumis Inc's revenue model is based on the development and potential future commercialization of its TYK2 inhibitor pipeline. The company's products target specific disease areas including plaque psoriasis, systemic lupus erythematosus, Uveitis, and neurodegenerative conditions. The clinical-stage focus indicates that revenue will likely come from partnerships, licensing agreements, or eventual product sales once approved. The company's data analytics platform supports target identification for immune-mediated indications, which may lead to additional pipeline assets. Alumis is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Alumis's Liabilities

Alumis's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Alumis's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Alumis's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Alumis's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Alumis’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Alumis stock

The Liabilities of Alumis is 110.64 M USD in 2025.

The Liabilities of Alumis changed from 80.89 M USD to 110.64 M USD, representing a 36.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Alumis since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Alumis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Alumis

All Key Metrics — Alumis